A key opinion leader discusses the CARD Study and how the emerging data has impacted the treatment of prostate cancer.
EP. 1: Counseling Patients About Therapy Selection
EP. 2: CARD Study: Pain Response and Quality of Life Analysis
EP. 3: CARD Trial Regimen After AR-Targeted or Chemotherapy
EP. 4: Advanced Disease: AR-Targeted or Chemotherapy?
EP. 5: AR-Targeted Therapy MORE and Cross Resistance
EP. 6: The Future of Advanced Prostate Cancer Management
Genomic test can predict resistance to chemotherapy in prostate cancer
177Lu-rhPSMA-10.1 injection shows positive radiation dosimetry results in mCRPC
Phase 3 data of oral sulopenem for uUTIs published in NEJM Evidence
FDA grants RMAT designation to detalimogene voraplasmid for high-risk NMIBC